KR20240099311A - 제제 - Google Patents

제제 Download PDF

Info

Publication number
KR20240099311A
KR20240099311A KR1020247016530A KR20247016530A KR20240099311A KR 20240099311 A KR20240099311 A KR 20240099311A KR 1020247016530 A KR1020247016530 A KR 1020247016530A KR 20247016530 A KR20247016530 A KR 20247016530A KR 20240099311 A KR20240099311 A KR 20240099311A
Authority
KR
South Korea
Prior art keywords
antibody
liquid formulation
buffer
stable liquid
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247016530A
Other languages
English (en)
Korean (ko)
Inventor
클라우데 페에르보옴
마이클 조셉 에두아르 부넨
Original Assignee
유씨비 바이오파마 에스알엘
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 유씨비 바이오파마 에스알엘 filed Critical 유씨비 바이오파마 에스알엘
Publication of KR20240099311A publication Critical patent/KR20240099311A/ko
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591Stabilisation, fragmentation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
KR1020247016530A 2021-10-21 2022-10-20 제제 Pending KR20240099311A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2115121.2 2021-10-21
GBGB2115121.2A GB202115121D0 (en) 2021-10-21 2021-10-21 Formulations
PCT/EP2022/079182 WO2023067049A1 (en) 2021-10-21 2022-10-20 Formulations

Publications (1)

Publication Number Publication Date
KR20240099311A true KR20240099311A (ko) 2024-06-28

Family

ID=78806158

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247016530A Pending KR20240099311A (ko) 2021-10-21 2022-10-20 제제

Country Status (17)

Country Link
US (1) US20240415769A1 (https=)
EP (1) EP4419078A1 (https=)
JP (1) JP2024539265A (https=)
KR (1) KR20240099311A (https=)
CN (1) CN118119377A (https=)
AR (1) AR127421A1 (https=)
AU (1) AU2022372646A1 (https=)
CA (1) CA3235381A1 (https=)
CL (1) CL2024001229A1 (https=)
CO (1) CO2024006193A2 (https=)
GB (1) GB202115121D0 (https=)
GE (2) GEAP202416520A (https=)
IL (1) IL312207A (https=)
MX (1) MX2024004872A (https=)
PE (1) PE20241193A1 (https=)
TW (1) TW202323288A (https=)
WO (1) WO2023067049A1 (https=)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006100679A2 (en) 2005-03-22 2006-09-28 Quark Pharmaceuticals, Inc. Recombinant antibodies against human type ii transglutaminase and uses thereof
GB2490655A (en) 2011-04-28 2012-11-14 Univ Aston Modulators of tissue transglutaminase
GB201209096D0 (en) 2012-05-24 2012-07-04 Medical Res Council Technology Compounds
GB201411320D0 (en) 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct
CN109563161A (zh) * 2016-02-03 2019-04-02 安口生物公司 用于提高抗体稳定性的缓冲制剂

Also Published As

Publication number Publication date
AU2022372646A1 (en) 2024-06-06
GEAP202416520A (en) 2024-07-25
AR127421A1 (es) 2024-01-24
GB202115121D0 (en) 2021-12-08
GEP20257800B (en) 2025-09-25
CN118119377A (zh) 2024-05-31
JP2024539265A (ja) 2024-10-28
TW202323288A (zh) 2023-06-16
CA3235381A1 (en) 2023-04-27
US20240415769A1 (en) 2024-12-19
MX2024004872A (es) 2024-05-06
PE20241193A1 (es) 2024-06-03
IL312207A (en) 2024-06-01
EP4419078A1 (en) 2024-08-28
CL2024001229A1 (es) 2024-09-13
CO2024006193A2 (es) 2024-05-30
WO2023067049A1 (en) 2023-04-27

Similar Documents

Publication Publication Date Title
AU2015260758B2 (en) Antibody formulation
KR100996801B1 (ko) 항-MAdCAM 항체 조성물
KR101782203B1 (ko) 동결건조 및 수성 항-cd40 항체 제제
KR20170117166A (ko) 단클론 항체를 위한 안정한 액체 제형
CN105051064A (zh) 抗TNF-α抗原结合蛋白
KR102106914B1 (ko) Gm-csf를 중화하는 화합물을 포함하는 액체 제제
US20240342083A1 (en) Anti-pd-1 antibody pharmaceutical composition and use thereof
JP2023535433A (ja) Pd-l1/lag-3二重特異性抗体製剤およびその調製方法ならびに使用
KR20240109250A (ko) 항ox40 단일클론 항체를 포함하는 약학적 제제
US20250263494A1 (en) Anti-tl1a antibody formulations
KR20240099311A (ko) 제제
US20260115137A1 (en) Stable formulations of a multivalent vhh based cytotoxic t lymphocyte associated antigen 4 (ctla4) binder binding to human ctla4 and methods of use thereof
TW202511293A (zh) 包含抗ccr8抗體的製劑及其用途
KR20240099316A (ko) 제제
HK40109650A (zh) 制剂
HK40109619A (zh) 制剂
RU2844800C2 (ru) Фармацевтическая композиция на основе антитела против PD-1 и ее применение
KR20230026407A (ko) 액티빈 a 항체 제형 및 이의 사용 방법

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20240517

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application